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Coronary heart disease (CHD) morbidity, disability and
mortality remain high in the U.S. and constitute a major
challenge to medical science and public health. Annual
economic costs (direct and indirect) of cardiovascular dis-
eases (CVD) in this country in 2001 are estimated to exceed
$298.2 billion (1).
Over the last half-century, a remarkable pattern has been
observed in trends of the CHD epidemic. Between 1940
and 1967, CHD mortality rates rose for all people aged 35
to 74 years. This upward trend was recorded for white men,
black men and black women, but not for white women.
Since 1968, the trend has reversed i.e., CHD death rates
have decreased steadily, with an overall decline of over 50%.
This downward trend has involved all age-gender-ethnic
groups in the adult population and all regions of the
country, but it is less steep for lower socioeconomic strata
(SES). It has encompassed both main categories of CHD
(i.e., acute myocardial infarction [MI] and chronic ischemic
heart disease) but much more so for acute MI than for
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CHD (2). The U.S. decline in CHD mortality rates is one
of the largest—absolutely and relatively—of such trends in
industrialized countries (3), but in the 1990s the rate of
decline slowed. The drop in CHD mortality rates has been
accompanied by an even greater percentage decrease in
death rates from stroke, but—again—with a leveling off of
the downward trend in the 1990s. During these decades,
death rates from the major CVD and all causes also fell
substantially, reflecting the declines in CHD and stroke
among all strata of the population, in both men and women
from ages 35 on, but—again—less so for lower SES strata.
In terms of life expectancy, for men particularly an earlier
adverse trend was reversed, with prevention of premature
death for hundreds of thousands of individuals since 1968.
As experience with control of earlier epidemics has taught
us, both prevention and conquest of mass disease require a
proper national public policy and its implementation
throughout the population. The U.S. was one of the
first—if not the first—country to develop public policy in
response to adverse CHD–CVD trends in the 1950s and
early 1960s. This was done particularly under the leadership
of the American Heart Association (AHA), and other
professional, voluntary and public organizations (e.g., the
American College of Cardiology, the Inter-Society Com-
mission for Heart Disease Resources, the National Heart,
Lung and Blood Institute). In 1959, the AHA issued its
first statement on smoking and CVD health, and two years
later it proposed a landmark dietary intervention against too
high serum cholesterol levels (4). Subsequently, statements
concerning all the major CHD risk factors were released,
including reports on drug treatment of high blood pressure.
Corresponding policy was adopted by the federal govern-
ment, beginning with the historic “Report to the Surgeon
General on Smoking and Health” in 1964 (5) and continu-
ing with the White House Conference on Food, Nutrition
and Health in 1970 (6), the National High Blood Pressure
Education Program in 1972, the Senate Select Committee
on Nutrition and Human Needs in 1977 (7) and the
National Cholesterol Education Program some years later
(8). These were followed in subsequent years by other
government policy commitments for CVD–CHD preven-
tion, which have been extended in important ways in the
1980s and 1990s, and have received broad support from
major national organizations of physicians and other health
professionals (9–13).
In the U.S. and other countries throughout these decades,
resources allocated to implement such policies by the
national government and by voluntary and private organi-
zations have been modest compared, for example, to expen-
ditures by the big tobacco companies on advertising, lobby-
ing and support for political candidates. Nevertheless, a
good deal has been accomplished; the prevention efforts
have reached “critical mass.” The concern of the population,
its readiness to respond and its positive responses are
documented in both “subjective” and “objective” data. For
example, in a 1977 nutritional survey by the U.S. Depart-
ment of Agriculture (14) on a sample of the American
population, approximately two-thirds indicated they had
made changes in their eating habits in the previous three
years for health and nutrition reasons. The reported types of
change were related to dietary fats, sugars, salt, calories,
blood cholesterol, blood pressure, diabetes and so forth. The
two most important reasons given for the changes were
advice from a health professional and information from the
mass media. These “subjective” statements find their coun-
terpart in national data indicating improvements in food
intake patterns, including declines in dietary cholesterol and
saturated fat intake that are substantial, albeit less than
national goals. Concordant with the favorable dietary
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trends, declines have occurred in average serum cholesterol
of adult population samples, from about 235 mg/dl in the
1950s to about 225 mg/dl in the early 1960s to 205 mg/dl
in the late 1980s and early 1990s. Indeed, by the year 2000
the average serum cholesterol of adults is estimated to have
reached the national health goal of no more than 200 mg/dl
(15). Clearly, this downward trend—all the more remark-
able in view of the steady increase in weight of adults—was
for a long time unrelated to drugs (i.e., based on improve-
ment in the composition of the diet). Only in the 1990s,
with the emergence of the statins, have drugs played an
important part in implementing serum cholesterol goals.
Data also indicate that population mean blood pressure
levels are down (16), in part independent of antihyperten-
sive drug treatment. Moreover, national statistics document
impressive rates of smoking cessation and of decline in the
proportion of the population currently smoking (17), al-
though recent trends among teenagers and young adults are
adverse (15,18), and long-term trends are much less favor-
able for lower SES (15,17).
Given the dramatic nature of these trends and their
importance for public health and for medical care, there has
been considerable research interest in their causes and
consequences. Investigations have assessed both the efficacy
of medical interventions and the economic implications of
preventive and therapeutic interventions directed against
heart disease and its risk factors.
In this issue of the Journal, Goldman et al. (19) attempt
to answer the question “what was the aggregate impact and
cost-effectiveness of interventions that were actually imple-
mented in the entire population [ages 35 to 84] between
1981 and 1990?” This is an important query from the point
of view of medical care, public health, and of what we get for
money invested. The investigators are not projecting what
might be accomplished if certain changes or interventions
were made; instead, they are modeling what actually hap-
pened in terms of changes in blood pressure, blood choles-
terol, smoking and the associated costs of screening and
interventions to decrease these coronary risk factors. Using
data from 1981 to 1990, they quantify the decrease in costs
of the disease due to lower incidence, and the increase in
costs for intervention to accomplish this decline in disease,
and they compute the net cost by subtracting the one from
the other. To arrive at a measure of “cost-effectiveness,” they
estimate the quality-adjusted additional years of life attrib-
utable to the observed reductions in risk-factor levels and
disease events, and they divide the net costs by the years of
life gained to arrive at a cost per additional quality-adjusted
year of life (QAYL), attributable to reduction in each major
risk factor, and overall. Recognizing that the full impact of
risk-factor reductions and total costs of intervention does
not occur until after the period they modeled, the research-
ers make projections from 1991 to 2015, assuming that the
1990 levels of risk-factor reduction will be maintained
throughout this period.
Based on this computer simulation (20), Goldman et al.
(19) come to a very positive bottom line, particularly since
projections into 2015 (i.e., over a 35-year period) yield far
more favorable cost and cost-effectiveness estimates than for
the shorter period of 1981 to 1990. For example, estimated
costs for observed reductions in blood pressure per QAYL
gained is $95,000 between 1981 and 1990 but only $6,800
for the period 1981 to 2015. For this period, their model
predicts reductions in CHD deaths to be 100,000,
1,300,000 and 2,400,000 for risk-factor reductions in smok-
ing, serum cholesterol, and blood pressure, respectively,
with an overall reduction of 3,600,000 deaths due to the
combined effects of reductions in all three major risk factors.
They further predict QAYL gained from these risk-factor
reductions to be 6,600,000, 6,500,000 and 22,000,000 for
reductions in smoking, serum cholesterol, and blood pres-
sure, respectively; 33,000,000 QAYL gained overall from
reductions in all risk factors over the period 1981 to 2015.
These dramatic reductions in CHD deaths and resultant
substantial increases in years of life gained from reductions
in risk factors lead to a prediction of an overall cost-
effectiveness ratio of $5,400 per QAYL gained over the
35-year period. Thus, as the investigators (19) state: “Over-
all we believe our analysis is a strong endorsement of the
investment in risk factor reduction in the period 1981 to
1990. Maintenance of these improvements should yield
incremental benefit with even more favorable cost-
effectiveness ratios.”
Of course, these results are based on assumptions and
estimates; therefore, they are subject to criticism related to
the soundness of the assumptions, the parameters of the
model, and the quality of the data used for making esti-
mates. However, the model employed has been widely
utilized in numerous studies, and its predictive capacity has
been extensively tested and documented (20,21). Likewise,
careful judgment apparently was used in choosing data for
estimates of disease rates, costs of disease and costs of
risk-factor reductions, and appropriate sensitivity analyses
were carried out to gauge the effects of inaccuracies in
estimates. Overall, with consideration of such caveats, the
results are a strong endorsement for efforts and investments
toward risk-factor reduction made in the U.S. over the past
20 years. The investigators (19) provide further significant
documentation that reductions in CHD incidence and
death and increased years of high-quality life have resulted
from reductions in risk factors, and that these accomplish-
ments were achieved with cost-effectiveness acceptable to
the health policy community.
Nevertheless, within the context of this impressive “bot-
tom line,” there remains the need to be fully aware of
remaining challenges: the flank of the CHD epidemic has
been turned, but it continues, and there are no assurances of
further favorable downward trends. The estimated costs of
treating CHD are enormous ($730 billion over the period
1981 to 2015 according to Goldman et al. [19]), and the
costs of risk-factor reduction—through both population-
wide programs and patient-specific interventions—are large
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as well ($350 billion estimated for the same period). Despite
reductions in CHD incidence due to lower risk-factor levels,
Goldman et al. (19) estimate that the costs of risk-factor
reductions still create “about a 15% net increase in the total
burden of CHD costs,” compared to no interventions.
Moreover, although $5,400 per QAYL gained may be
judged “cost-effective” by many, it is a substantial amount,
much of which must be borne by society as a whole rather
than solely by the individuals who benefit from the added
years of life. Therefore, it is reasonable to ask whether
further reductions in risk-factor levels can be achieved,
whether these reductions can lead to additional decreases in
disease, and whether this could be accomplished with better
cost-effective measures. These matters were, of course, not
encompassed in the goals of the Goldman et al. (19) report.
Still, it may be of interest to explore along these lines with
the hope both of stimulating additional research with the
model and highlighting potential population-wide benefits
of crucial strategic emphases related to prevention and
control of major risk factors.
One area for exploration relates to the levels chosen to
characterize blood pressure and cholesterol in the investi-
gators’ CHD Policy Model. It uses diastolic blood pressure
(DBP) levels ,95, 95 to 104, .104 mm Hg and serum
cholesterol levels ,240, 240 to 299, .299 mg/dl. Thus, the
lowest category of both these variables includes numerous
individuals with elevated levels, placing them at increased
risk compared to favorable or optimal levels—for systolic
blood pressure (SBP)/DBP, #120/#80 mm Hg; for serum
cholesterol, #200 mg/dl, per current policy recommenda-
tions (13,22,23). Would results with the model be different
were these preferred levels chosen? Also, given recent
evidence that SBP is a more sensitive and stable predictor of
CHD (24,25), what would be the effect of substituting
systolic for diastolic pressure—or including both pressures
as a single categoric variable (see the preceding text), as is
done in the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure (JNC)
VI criteria (23)?
Our recent work with individuals who have favorable or
optimal levels of all three major CHD risk factors and are
without a history of diabetes or myocardial infarction shows
that these individuals have a remarkable set of positive
outcomes in terms of much lower CHD, stroke, CVD and
all-causes mortality, greater longevity, lower CVD and total
Medicare expenditures for health care, and higher quality of
life (26–28). These results, achieved from long-term obser-
vation of large cohorts, confirm statistical estimates from the
Framingham and national cooperative Pooling Project stud-
ies (29–31). Those smaller studies had to extrapolate for
assessment of impact of low risk as there were too few
people at low risk (prevalence about 5%) for measurement.
Availability of actual data at the end of the twentieth
century demonstrate unequivocally that young adults and
middle-aged American men and women with favorable
levels of all major risk factors are indeed at remarkably low
long-term risk of CHD–CVD, and they have considerably
longer life expectancy with health. Thus, it would be
valuable to learn whether the model is sensitive to the choice
of major risk-factor cut-points, yielding significantly differ-
ent results with projections made relative to individuals at
favorable rather than frankly elevated levels of these risk
factors.
A similar argument can be advanced regarding the age
range (35 to 84 years) used in the projections. By age 35,
lifestyles have already been set for decades, all too frequently
with resultant adverse risk-factor levels already in place for
years. Thus, the model begins at a point where risk-factor
levels have already been rising for years. Inevitably, then, the
model concentrates on efforts to reverse this trend of
increasing risk-factor levels, with no consideration for ef-
forts—crucial to achieve low risk early on—at primary or
primordial prevention that could be applied in childhood,
youth, and young adulthood at relatively low cost to prevent
the rise (rather than just treat the elevation) of these risk
factors. The relevance of a focus along these lines is
underscored by the fact—evident from repeated national
and local surveys—that population median levels of SBP/
DBP and serum cholesterol are favorable at ages 18 to 24
years. The challenge is the preservation of these levels with
little or no rise. The scientific knowledge is available as to
what needs to be done (32–35).
Another area for attention relates to the costs of antihy-
pertensive and cholesterol-lowering interventions, which in
this model are largely driven by the costs of medications. In
their sensitivity analysis, Goldman et al. (19) demonstrate
that changing to lower-cost antihypertensive medications (a
40% savings) reduces the cost-effectiveness ratio from
$5,400 to $2,400 per QAYL. This inspires the possibility of
even greater cost reductions from substitution of expensive
pharmacologic approaches by much lower cost nutritional
and lifestyle improvements for lowering risk-factor levels.
Goldman et al. (19) offer data showing that population-
based educational programs are likely responsible for wide-
spread reductions in risk-factor levels and are at the same
time highly cost-effective. This is especially intriguing given
that the model incorporated projected increases in mean
body mass index (BMI) levels during the simulation period
with no mention of costs associated with treatment or
prevention. The adverse trend in BMI must be viewed with
concern equal to that given to unfavorable trends in blood
pressure and serum cholesterol. There is no reason to regard
increase in any of these measures as an inevitable conse-
quence of aging.
All these adverse trends of today are societal in origin,
either absent or of low order in other societies, and are
remediable in ours. Substantially increased national efforts
to promote healthy eating patterns and increased physical
activity at every age can produce lower mean population
levels of BMI and consequent further nonpharmacological
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reductions in mean blood pressure and serum cholesterol
beyond those already achieved, as well as reduced incidence
and prevalence of diabetes. Almost certainly this would
further reduce disease and be cost-effective. The investiga-
tors (19) state that their data could not be used to separate
the epidemiologic benefits of patient-specific compared to
population-wide interventions. It would be valuable to
extend the model to simulate and explore the matter of
comparative cost-effectiveness of long-term population-
wide lifestyle interventions versus pharmacological interven-
tions.
Implicit in the good news of the Goldman et al. (19)
report is the acceptance of widespread lifelong costly phar-
macological interventions to curtail smoking and hold back
the tide of increasing blood pressure and cholesterol levels.
With this acceptance comes the realization that monies for
these endeavors flow largely from the federal government
and may not continue to be appropriated. This highlights
the key strategic challenge facing the medical and health
policy community at the beginning of this century. Do we
resign ourselves to a strategy emphasizing treatment of
results of disease (secondary prevention) and lowering of
already elevated risk factors, or emphasize a strategy focused
on prevention of the risk factors themselves? The former
approach means endless—decade after decade—efforts to
treat risk factors and disease as they come down the road.
Only the latter emphasis—namely prevention of the major
risk factors in the first place—has the potential to end the
CHD epidemic by progressively improving lifestyles in all
strata of the population, from conception on, so that people
with adverse risk-factor levels become the exception rather
than the rule, and people with favorable levels of all major
risk factors—low-risk people—become the rule rather than
the exception. Key to the successful implementation of this
strategy is the recognition of the unsolved problem of
improving risk profiles among lower SES strata. Research
and policy must address the widening gap between the
affluent and the poor in terms of cardiovascular risk, and
adequate resources must be allocated to its solution.
Finally, the strong positive message of the Goldman et al.
(19) article is that present efforts to combat the epidemic of
CHD are cost-effective and represent a worthwhile social
investment. With elimination of rise in risk-factor levels
with age across all strata of the population irrespective of
region, ethnicity, and SES—through concentrated efforts at
primary and primordial prevention—further reductions in
coronary disease rates and cessation of the epidemic (with
better cost-effectiveness) are achievable goals for the next
decades.
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